We have standardized, GMP drug candidates available today for licensing to qualified partners.
Filament has in-house regulatory and logistics expertise across a range of jurisdictions, and all of our drug candidates are proudly manufactured in Canada.
We are committed to furthering psychedelic research and have licensing partnerships with leading researchers, institutions, and organizations around the world.
Our manufacturing facility has the capacity to supply every psilocybin clinical trial in the world.
Filament Health’s drug candidates are currently being studied in multiple clinical trials.
Filament is undertaking a clinical development program in order to apply for marketing authorization in various jurisdictions. The safety and efficacy of our products has not been formally established.
For more information about all clinical trials in your area visit:
Through Health Canada’s Special Access Program (SAP), healthcare professionals may request access to non-marketed drugs to treat patients with serious or life-threatening conditions. Access to these drugs is only considered when conventional therapies have failed, are unsuitable, or are unavailable.
SAP authorization allows a manufacturer to sell a drug that has not been approved for sale in Canada.
Visit the Health Canada website for information on requesting special access to an unapproved drug.
We provide our psilocybin drug candidate, as well as support with applications, free of charge for the SAP.